What is the appropriate treatment regimen for an ulcerative colitis flare?

Treatment of Ulcerative Colitis Flare

For mild-to-moderate UC flares, start with standard-dose oral mesalamine 2-3 g/day combined with rectal mesalamine 1 g/day; if inadequate response after 10-14 days or moderate disease at presentation, escalate to oral prednisolone 40 mg daily tapered over 6-8 weeks. 1, 2

Treatment Algorithm by Disease Severity and Location

Mild-to-Moderate Distal UC (Proctitis/Proctosigmoiditis)

First-line therapy:

• Rectal mesalamine 1 g/day (suppositories for proctitis, enemas for proctosigmoiditis) PLUS oral mesalamine 2-4 g/day 1, 3
• This combination is more effective than either agent alone 3
• Once-daily dosing is as effective as divided doses and improves adherence 1

Second-line (if inadequate response after 2 weeks):

• Escalate to high-dose oral mesalamine (>3 g/day, up to 4.8 g/day) with rectal mesalamine 1, 4
• If rectal mesalamine is not tolerated, substitute with rectal corticosteroids (though less effective than rectal mesalamine) 3

Third-line (if no sustained remission after 40 days of optimized 5-ASA):

• Oral prednisolone 40 mg daily, taper over 6-8 weeks 3, 2
• Alternative: Budesonide MMX 9 mg daily for those wishing to avoid systemic steroids (particularly effective for left-sided disease) 2, 4

Mild-to-Moderate Extensive/Left-Sided UC

First-line therapy:

• Oral mesalamine 2-3 g/day PLUS rectal mesalamine 1 g/day 1, 4
• For moderate disease activity at presentation, consider starting with high-dose mesalamine 4-4.8 g/day plus rectal mesalamine 1, 2

Second-line (suboptimal response after 10-14 days or persistent rectal bleeding beyond 2 weeks):

• Oral prednisolone 40 mg daily 3, 2, 4
• Taper gradually over 6-8 weeks; more rapid reduction increases early relapse risk 3
• Alternative: Budesonide MMX 9 mg daily (though less effective for extensive disease than left-sided) 2, 4

Third-line (steroid-dependent or steroid-refractory disease):

• Escalate to advanced therapies (see moderate-to-severe section below) 2, 5

Moderate-to-Severe UC (Including Steroid-Dependent/Refractory)

The AGA strongly recommends the following advanced therapies over no treatment 5:

Preferred agents (strong recommendation, high-quality evidence):

• TNF antagonists: Infliximab, golimumab
• Anti-integrin: Vedolizumab
• JAK inhibitors: Tofacitinib, upadacitinib (FDA-labeled for TNF-failure patients in US)
• Anti-IL-12/23: Ustekinumab
• S1P modulators: Ozanimod, etrasimod
• Anti-IL-23: Risankizumab, guselkumab

Conditional recommendation (moderate evidence):

• Adalimumab, filgotinib, mirikizumab

Key implementation points:

• Combine TNF antagonists with immunomodulators (azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day) for improved outcomes 5
• For non-TNF biologics, combination with immunomodulators has insufficient evidence 5
• Extended induction regimens (up to 16 weeks) or dose escalation may benefit patients with severe disease 5
• Avoid thiopurine or methotrexate monotherapy for active disease 5

Acute Severe UC (Hospitalized Patients)

Immediate management:

• Intravenous hydrocortisone 100 mg four times daily (or methylprednisolone 60 mg/day) 3, 6
• Unprepared flexible sigmoidoscopy to assess severity and exclude CMV colitis 6
• Subcutaneous heparin for VTE prophylaxis 3, 6
• IV fluid/electrolyte replacement, blood transfusion to maintain Hgb >10 g/dL 3
• Daily monitoring: vital signs (4x/day), stool chart, FBC, CRP, electrolytes 3, 6
• Joint gastroenterology-surgery management from admission 3, 6

Rescue therapy (if insufficient response by Day 3):

• Infliximab 5 mg/kg OR cyclosporin 4, 6
• Both have comparable efficacy; choice depends on local expertise 4
• For high inflammatory burden/hypoalbuminemia, consider accelerated/intensified infliximab dosing 7
• Emerging evidence: Upadacitinib shows promise as salvage therapy when IV steroids and infliximab fail 7

Surgical consultation:

• Consider colectomy if no response to 7 days of rescue therapy or earlier if clinical deterioration 6
• Expected colectomy rate during admission should be <30% in specialist centers 6
• Mortality should be <1% with appropriate management 6

Critical Pitfalls to Avoid

1. Do not delay corticosteroids waiting for stool cultures in severe disease—treatment should not wait for microbiological analysis 3

2. Do not use probiotics, curcumin, or FMT in active disease—these risk delaying proven effective therapy 1

3. Do not continue 5-ASA monotherapy beyond 40 days without response—this delays appropriate escalation 4

4. Do not taper prednisolone faster than 6-8 weeks—rapid reduction increases early relapse 3, 2

5. Do not use sequential rescue therapy (e.g., cyclosporin after failed infliximab) except in highly selected cases at specialist centers—adverse event rate is 23% with serious infections in 6.7% 4

6. Do not use immunomodulator monotherapy (thiopurines/methotrexate) for inducing remission in active disease 5

7. In severe colitis, avoid total colonoscopy—risk of perforation; use unprepared flexible sigmoidoscopy only 6

8. Monitor for toxic megacolon (colon diameter ≥5.5 cm)—risk factors include hypokalemia, hypomagnesemia, anti-diarrheal use 4

De-escalation Considerations

• Stop 5-ASA once escalated to advanced therapies 5
• Do not withdraw TNF antagonists in patients achieving corticosteroid-free remission for ≥6 months on combination therapy 5
• Insufficient evidence to guide immunomodulator withdrawal in combination therapy 5